https://scholars.lib.ntu.edu.tw/handle/123456789/536460
標題: | XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in asia | 作者: | Kim Y.-H. Shim J. CHIA-TI TSAI Wang C.-C. Vilela G. Muengtaweepongsa S. Kurniawan M. Maskon O. Hsu L.F. Nguyen T.H. Thanachartwet T. Sim K. Camm A.J. XANAP investigators |
關鍵字: | Asia-pacific; Bleeding risk; Real world; Rivaroxaban; Stroke prevention | 公開日期: | 2018 | 出版社: | Wiley-Blackwell | 卷: | 34 | 期: | 4 | 起(迄)頁: | 418-427 | 來源出版物: | Journal of Arrhythmia | 摘要: | Background: ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non-inferior to warfarin for stroke/systemic embolism (SE) prevention in patients with non-valvular atrial fibrillation (NVAF), with a favorable benefit–risk profile. XANAP investigated the safety and effectiveness of rivaroxaban in routine care in Asia-Pacific. Methods: XANAP was a prospective, real-world, observational study in patients with NVAF newly starting rivaroxaban. Patients were followed at ~3-month intervals for 1 year, or for ?30 days after permanent discontinuation. Primary outcomes were major bleeding events, adverse events (AEs), serious AEs and all-cause mortality; secondary outcomes included stroke/SE. Major outcomes were adjudicated centrally. Results: XANAP enrolled 2273 patients from 10 countries: mean age was 70.5 years and 58.1% were male. 49.8% of patients received rivaroxaban 20 mg once daily (od), 43.8% 15 mg od and 5.9% 10 mg od. Mean treatment duration was 296 days, and 72.8% of patients had received prior anticoagulation therapy. Co-morbidities included heart failure (20.1%), hypertension (73.6%), diabetes mellitus (26.6%), prior stroke/non-central nervous system SE/transient ischemic attack (32.8%) and myocardial infarction (3.8%). Mean CHADS2, CHA2DS2-VASc and HASBLED scores were 2.3, 3.7 and 2.1, respectively. The rates (events/100 patient-years [95% confidence interval]) of treatment-emergent major bleeding, stroke and all-cause mortality were 1.5 (1.0-2.1), 1.7 (1.2-2.5) and 2.0 (1.4-2.7), respectively. Persistence was 66.2% at the study end. Conclusions: The real-world XANAP study demonstrated low rates of stroke and bleeding in rivaroxaban-treated patients with NVAF from Asia-Pacific. The results were consistent with the real-world XANTUS study and ROCKET AF. ? 2018 The Authors. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054738871&doi=10.1002%2fjoa3.12073&partnerID=40&md5=dc6ee9689037b906877144936ebaf9e0 https://scholars.lib.ntu.edu.tw/handle/123456789/536460 |
ISSN: | 1880-4276 | DOI: | 10.1002/joa3.12073 | SDG/關鍵字: | rivaroxaban; aged; all cause mortality; anticoagulant therapy; Article; Asia; atrial fibrillation; cardiovascular disease assessment; cerebrovascular accident; CHA2DS2-VASc score; CHADS2 score; cohort analysis; comorbidity; diabetes mellitus; drug efficacy; drug safety; female; follow up; HAS-BLED score; heart failure; heart infarction; human; hypertension; major clinical study; male; observational study; open study; outcome assessment; prospective study; transient ischemic attack; treatment duration |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。